Engelhardt G
Arzneimittelforschung. 1975 Nov;25(11):1723-37.
The substance 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol (WA 335) was examined for its antagonistic effects against histamine and serotonin, for its atropine-like properties as well as for a series of other qualities in comparison with cyproheptadine and pimethixene. The anti-histamine and anti-serotonin activities of compound WA 335 on the smooth muscle and the capillary do not only exceed that of cyproheptadine but also that of pimethixene. WA 335 shows an extremely strong binding to histamine and serotonin receptors. In the dose range in which it causes already an antamine effect, its oral absorption is very good. The anti-anaphylactic effect is much stronger than that of cyproheptadine. Like pimethixene and cyproheptadine, WA 335 has no distinct antagonistic qualities against bradykinin. The anticholinergic effects of WA 335 are dependent on the test object. In examinations on the bronchus of the guinea pig and the pupil of the mouse, the atropine-like efficiency corresponds to that of cyproheptadine; it is stronger on the stimulated vagus of the cat and less efficient than cyproheptadine on the stomach of the rat. WA 335 has distinct central atropine-like properties. It possesses a strong surface anesthetic activity. The effects of WA 335 on circulation are dependent on species. In contrast to pimethixene, compound WA 335 like cyproheptadine potentiates the effects of norepinephrine in cats. The reduction of the carotid sinus reflex in the cat is more distinct after WA 335 than after pimethixene and corresponds to that produced by cyproheptadine. Higher doses of WA 335 than are necessary to demonstrate antaminic effects are needed to provoke central nervous effects. WA 335 shows no analgesic potency in mice. The influence on body temperature in the rat is similar to that of cyproheptadine. WA 335 is equally efficient as pimethixene with regard to the inhibition of spontaneous motility and prolongation of barbiturate sleep in mice, and shows the same anti-emetic activity as does chlorpromazine in dogs. In contrast to chlorpromazine the behaviour of dogs and cats is distinctly altered already by doses of WA 335 which cause a slight sedation.
对物质9,10 - 二氢 - 10 -(1 - 甲基 - 4 - 哌啶叉基)- 9 - 蒽醇(WA 335)进行了研究,比较其与赛庚啶和匹美噻嗪相比,对组胺和5 - 羟色胺的拮抗作用、阿托品样性质以及一系列其他性质。化合物WA 335对平滑肌和毛细血管的抗组胺和抗5 - 羟色胺活性不仅超过赛庚啶,也超过匹美噻嗪。WA 335显示出与组胺和5 - 羟色胺受体极强的结合力。在其已产生抗组胺作用的剂量范围内,其口服吸收非常好。其抗过敏性作用比赛庚啶强得多。与匹美噻嗪和赛庚啶一样,WA 335对缓激肽没有明显的拮抗性质。WA 335的抗胆碱能作用取决于测试对象。在豚鼠支气管和小鼠瞳孔的实验中,其阿托品样效能与赛庚啶相当;在猫的刺激迷走神经实验中作用更强,而在大鼠胃实验中比赛庚啶作用弱。WA 335具有明显的中枢阿托品样性质。它具有很强的表面麻醉活性。WA 335对循环的影响因物种而异。与匹美噻嗪不同,化合物WA 335与赛庚啶一样能增强猫体内去甲肾上腺素的作用。在猫中,WA 335使颈动脉窦反射减弱的作用比匹美噻嗪更明显,且与赛庚啶产生的作用相当。引发中枢神经作用所需的WA 335剂量高于显示抗组胺作用所需的剂量。WA 335在小鼠中无镇痛效力。其对大鼠体温的影响与赛庚啶相似。在抑制小鼠自发活动和延长巴比妥类药物睡眠时间方面,WA 335与匹美噻嗪同样有效,且在犬中显示出与氯丙嗪相同的抗呕吐活性。与氯丙嗪不同,在犬和猫中,引起轻微镇静的WA 335剂量就能明显改变其行为。